Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Sell
43
PTCT Quote, Financials, Valuation and Earnings
Last price:
$57.10
Seasonality move
:
12.15%
Day range:
$55.73 - $57.34
52-week range:
$24.00 - $58.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.44x
P/B ratio:
--
Volume:
1M
Avg. volume:
784.3K
1-year change:
89.39%
Market cap:
$4.5B
Revenue:
$806.8M
EPS (TTM):
-$4.73
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PTCT
PTC Therapeutics
|
$166.2M | -$1.24 | 119.66% | -34.58% | $64.93 |
|
BIIB
Biogen
|
$2.3B | $4.10 | -1.89% | 33.96% | $201.18 |
|
DSGN
Design Therapeutics
|
-- | -$0.30 | -- | -40% | $7.33 |
|
EDIT
Editas Medicine
|
$1.3M | -$0.42 | -23.05% | -22.53% | $3.75 |
|
OLMA
Olema Pharmaceuticals
|
-- | -$0.57 | -- | -5.36% | $26.00 |
|
VYGR
Voyager Therapeutics
|
$16.6M | -$0.35 | -30.56% | -119.44% | $16.10 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PTCT
PTC Therapeutics
|
$57.14 | $64.93 | $4.5B | -- | $0.00 | 0% | 5.44x |
|
BIIB
Biogen
|
$140.90 | $201.18 | $20.6B | 12.59x | $0.00 | 0% | 2.13x |
|
DSGN
Design Therapeutics
|
$4.65 | $7.33 | $263.9M | -- | $0.00 | 0% | -- |
|
EDIT
Editas Medicine
|
$1.31 | $3.75 | $108.7M | -- | $0.00 | 0% | 3.34x |
|
OLMA
Olema Pharmaceuticals
|
$4.24 | $26.00 | $289.7M | -- | $0.00 | 0% | -- |
|
VYGR
Voyager Therapeutics
|
$3.88 | $16.10 | $214.2M | 6.11x | $0.00 | 0% | 2.80x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PTCT
PTC Therapeutics
|
186.52% | -0.744 | 67.49% | 2.23x |
|
BIIB
Biogen
|
27.36% | 0.257 | 28.25% | 0.77x |
|
DSGN
Design Therapeutics
|
-- | 1.827 | -- | -- |
|
EDIT
Editas Medicine
|
-- | 0.335 | -- | 3.71x |
|
OLMA
Olema Pharmaceuticals
|
-- | 2.115 | -- | -- |
|
VYGR
Voyager Therapeutics
|
-- | 1.754 | -- | 5.45x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PTCT
PTC Therapeutics
|
$196.9M | -$15.9M | -382.54% | -- | -25.16% | -$36.5M |
|
BIIB
Biogen
|
$1.9B | $450.6M | 7.33% | 10.33% | 14.32% | $694.6M |
|
DSGN
Design Therapeutics
|
-- | -$16.7M | -- | -- | -- | -$9.9M |
|
EDIT
Editas Medicine
|
-- | -$34.4M | -100% | -100% | -112.28% | -$51.3M |
|
OLMA
Olema Pharmaceuticals
|
-- | -$36.8M | -- | -- | -- | -$26.3M |
|
VYGR
Voyager Therapeutics
|
-- | -$38.3M | -21.07% | -21.07% | -610.05% | -$14.7M |
PTC Therapeutics vs. Competitors
-
Which has Higher Returns PTCT or BIIB?
Biogen has a net margin of -30.91% compared to PTC Therapeutics's net margin of 10.87%. PTC Therapeutics's return on equity of -- beat Biogen's return on equity of 10.33%.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics92.36% -$0.85 $1.3B BIIBBiogen76.23% $1.83 $23B -
What do Analysts Say About PTCT or BIIB?
PTC Therapeutics has a consensus price target of $64.93, signalling upside risk potential of 13.63%. On the other hand Biogen has an analysts' consensus of $201.18 which suggests that it could grow by 42.79%. Given that Biogen has higher upside potential than PTC Therapeutics, analysts believe Biogen is more attractive than PTC Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics6 4 1 BIIBBiogen13 17 0 -
Is PTCT or BIIB More Risky?
PTC Therapeutics has a beta of 0.660, which suggesting that the stock is 34.007% less volatile than S&P 500. In comparison Biogen has a beta of 0.012, suggesting its less volatile than the S&P 500 by 98.773%.
-
Which is a Better Dividend Stock PTCT or BIIB?
PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or BIIB?
PTC Therapeutics quarterly revenues are $213.2M, which are smaller than Biogen quarterly revenues of $2.5B. PTC Therapeutics's net income of -$65.9M is lower than Biogen's net income of $266.7M. Notably, PTC Therapeutics's price-to-earnings ratio is -- while Biogen's PE ratio is 12.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 5.44x versus 2.13x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics5.44x -- $213.2M -$65.9M BIIBBiogen2.13x 12.59x $2.5B $266.7M
-
Which has Higher Returns PTCT or DSGN?
Design Therapeutics has a net margin of -30.91% compared to PTC Therapeutics's net margin of --. PTC Therapeutics's return on equity of -- beat Design Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics92.36% -$0.85 $1.3B DSGNDesign Therapeutics-- -$0.24 -- -
What do Analysts Say About PTCT or DSGN?
PTC Therapeutics has a consensus price target of $64.93, signalling upside risk potential of 13.63%. On the other hand Design Therapeutics has an analysts' consensus of $7.33 which suggests that it could grow by 57.71%. Given that Design Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Design Therapeutics is more attractive than PTC Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics6 4 1 DSGNDesign Therapeutics0 2 0 -
Is PTCT or DSGN More Risky?
PTC Therapeutics has a beta of 0.660, which suggesting that the stock is 34.007% less volatile than S&P 500. In comparison Design Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PTCT or DSGN?
PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Design Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Design Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or DSGN?
PTC Therapeutics quarterly revenues are $213.2M, which are larger than Design Therapeutics quarterly revenues of --. PTC Therapeutics's net income of -$65.9M is lower than Design Therapeutics's net income of -$13.7M. Notably, PTC Therapeutics's price-to-earnings ratio is -- while Design Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 5.44x versus -- for Design Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics5.44x -- $213.2M -$65.9M DSGNDesign Therapeutics-- -- -- -$13.7M
-
Which has Higher Returns PTCT or EDIT?
Editas Medicine has a net margin of -30.91% compared to PTC Therapeutics's net margin of -148.33%. PTC Therapeutics's return on equity of -- beat Editas Medicine's return on equity of -100%.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics92.36% -$0.85 $1.3B EDITEditas Medicine-- -$0.55 $134.3M -
What do Analysts Say About PTCT or EDIT?
PTC Therapeutics has a consensus price target of $64.93, signalling upside risk potential of 13.63%. On the other hand Editas Medicine has an analysts' consensus of $3.75 which suggests that it could grow by 186.26%. Given that Editas Medicine has higher upside potential than PTC Therapeutics, analysts believe Editas Medicine is more attractive than PTC Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics6 4 1 EDITEditas Medicine4 9 0 -
Is PTCT or EDIT More Risky?
PTC Therapeutics has a beta of 0.660, which suggesting that the stock is 34.007% less volatile than S&P 500. In comparison Editas Medicine has a beta of 1.876, suggesting its more volatile than the S&P 500 by 87.581%.
-
Which is a Better Dividend Stock PTCT or EDIT?
PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or EDIT?
PTC Therapeutics quarterly revenues are $213.2M, which are larger than Editas Medicine quarterly revenues of $30.6M. PTC Therapeutics's net income of -$65.9M is lower than Editas Medicine's net income of -$45.4M. Notably, PTC Therapeutics's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 5.44x versus 3.34x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics5.44x -- $213.2M -$65.9M EDITEditas Medicine3.34x -- $30.6M -$45.4M
-
Which has Higher Returns PTCT or OLMA?
Olema Pharmaceuticals has a net margin of -30.91% compared to PTC Therapeutics's net margin of --. PTC Therapeutics's return on equity of -- beat Olema Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics92.36% -$0.85 $1.3B OLMAOlema Pharmaceuticals-- -$0.40 -- -
What do Analysts Say About PTCT or OLMA?
PTC Therapeutics has a consensus price target of $64.93, signalling upside risk potential of 13.63%. On the other hand Olema Pharmaceuticals has an analysts' consensus of $26.00 which suggests that it could grow by 513.21%. Given that Olema Pharmaceuticals has higher upside potential than PTC Therapeutics, analysts believe Olema Pharmaceuticals is more attractive than PTC Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics6 4 1 OLMAOlema Pharmaceuticals5 0 0 -
Is PTCT or OLMA More Risky?
PTC Therapeutics has a beta of 0.660, which suggesting that the stock is 34.007% less volatile than S&P 500. In comparison Olema Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PTCT or OLMA?
PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Olema Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or OLMA?
PTC Therapeutics quarterly revenues are $213.2M, which are larger than Olema Pharmaceuticals quarterly revenues of --. PTC Therapeutics's net income of -$65.9M is lower than Olema Pharmaceuticals's net income of -$33.6M. Notably, PTC Therapeutics's price-to-earnings ratio is -- while Olema Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 5.44x versus -- for Olema Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics5.44x -- $213.2M -$65.9M OLMAOlema Pharmaceuticals-- -- -- -$33.6M
-
Which has Higher Returns PTCT or VYGR?
Voyager Therapeutics has a net margin of -30.91% compared to PTC Therapeutics's net margin of -549.33%. PTC Therapeutics's return on equity of -- beat Voyager Therapeutics's return on equity of -21.07%.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics92.36% -$0.85 $1.3B VYGRVoyager Therapeutics-- -$0.59 $299.8M -
What do Analysts Say About PTCT or VYGR?
PTC Therapeutics has a consensus price target of $64.93, signalling upside risk potential of 13.63%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.10 which suggests that it could grow by 314.95%. Given that Voyager Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Voyager Therapeutics is more attractive than PTC Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics6 4 1 VYGRVoyager Therapeutics11 0 0 -
Is PTCT or VYGR More Risky?
PTC Therapeutics has a beta of 0.660, which suggesting that the stock is 34.007% less volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.991, suggesting its less volatile than the S&P 500 by 0.87699999999999%.
-
Which is a Better Dividend Stock PTCT or VYGR?
PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or VYGR?
PTC Therapeutics quarterly revenues are $213.2M, which are larger than Voyager Therapeutics quarterly revenues of $6.3M. PTC Therapeutics's net income of -$65.9M is lower than Voyager Therapeutics's net income of -$34.5M. Notably, PTC Therapeutics's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 5.44x versus 2.80x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics5.44x -- $213.2M -$65.9M VYGRVoyager Therapeutics2.80x 6.11x $6.3M -$34.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Palantir a Good Stock to Buy?
Palantir Technologies (PLTR) stock soared to its highest level in…
Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
